Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Fenofibrate Cuts...

Fenofibrate Cuts Diabetic Retinopathy Risk by 27%: LENS Trial

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2024-08-20T12:16:27+05:30  |  Updated On 20 Aug 2024 4:39 PM IST
Fenofibrate Cuts Diabetic Retinopathy Risk by 27%: LENS Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

A groundbreaking trial presented for the first time at the ADA 2024 demonstrated that Fenofibrate significantly reduces the progression of diabetic retinopathy.

The LENS trial conducted across multiple centers is the first of its kind large scale trial specifically designed to investigate the effect of Fenofibrate on eye outcomes in people with early diabetic retinopathy.

This trial enrolled 1151 participants who were randomly assigned to receive 145 mg fenofibrate tablets or placebo. The primary outcome was a composite of developing referable diabetic retinopathy or maculopathy (based on Scotland’s Diabetic Eye Screening grading scheme) or treatment (intravitreal injection, retinal laser, vitrectomy) for retinopathy or maculopathy. The trial findings have been published in the latest issue of NEJM Evidence.

Over a median follow-up of 4.0 years, 131 participants (22.7%) in the fenofibrate group and 168 participants (29.2%) in the placebo group progressed to referable diabetic retinopathy or maculopathy, or required treatment (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.58 to 0.91; P=0.006). (Refer to Figure 1)

The occurrence of any retinopathy or maculopathy progression was also significantly less common with fenofibrate, 32.1% vs 40.2% with placebo (HR, 0.74). A comparable proportional reduction was noted for referable maculopathy, affecting 107 participants (18.6%) in the fenofibrate group and 149 participants (25.9%) in the placebo group (HR, 0.66). Macular edema occurred in 3.8% with fenofibrate vs in the 7.5% placebo group, which is also significant (HR, 0.50).

Allocation to fenofibrate, compared with placebo, had no effect on visual function, quality of life, or visual acuity


Figure 1: Referable Diabetic Retinopathy or Maculopathy, or Treatment for Diabetic Retinopathy or Maculopathy.

Shown are the results of the primary composite outcome of referable diabetic retinopathy or maculopathy, or treatment thereof, with intravitreal injection of medication, retinal laser therapy, or vitrectomy. The inset graph shows the same data on an expanded y-axis. The primary outcome occurred in 131 participants (22.7%) in the fenofibrate group and in 168 participants (29.2%) in the placebo group, representing 65 fewer primary outcome events per 1000 participants in the fenofibrate group than in the placebo group over a median of 4.0 years of follow-up.

Safety: No Major Concerns:

There was no difference between groups in major cardiovascular events or nontraumatic lower limb amputations and no effect on urine albumin: creatinine ratio. Total and non-HDL cholesterol were slightly lower, while triglyceride levels were a significant 13.7% lower with fenofibrate. The eGFR was 7.9 (95% CI, 6.8 to 9.1) ml/min/1.73 m2 lower in the fenofibrate group compared with the placebo group.

Retinal imaging substudies from cardiovascular outcome trial i.e. the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial and the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial have associated fenofibrate use with improvements in diabetic retinopathy.

In summary, for participants with early diabetic retinal changes, fenofibrate treatment resulted in a reduction in the progression of diabetic retinopathy compared to placebo.

Reference: David Preiss, Jennifer Logue, Emily Sammons, Mohammed Zayed, Jonathan Emberson, Rachel Wade,Karl Wallendszus, Will Stevens, Rosanna Cretney, Simon Harding, Graham Leese, Gemma Currie, and Jane Armitage.Effect of Fenofibrate on Progression of Diabetic Retinopathy. NEJM Evidence June 2024.DOI: 10.1056/EVIDoa2400179

fenofibratediabetic retinopathydiabetesretinopathymaculopathydiabetes managementdiabetic retinopathy treatmentroseday ffenofibrate in diabetesfenofibrate renal benefitslens triallens trial fenofibrate
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

Relevance of Pioglitazone in Indian T2DM Care Continuum

Relevance of Pioglitazone in Indian T2DM Care Continuum

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

View All

Journal Club Today

Study Shows Combination Therapy May Improve Survival in Severe Heart Disease

Study Shows Combination Therapy May Improve Survival in Severe Heart Disease

View All

Health News Today

Health Bulletin 04/June/2025

Health Bulletin 04/June/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok